Mesoblast (MEOBF) Net Cash Flow (QoQ) (2016 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) Net Cash Flow (QoQ) (2016 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 285.72% |
| Mar 31, 2023 | -656.95% |
| Dec 31, 2022 | -73.51% |
| Sep 30, 2022 | 436.58% |
| Jun 30, 2022 | 10.72% |
| Mar 31, 2022 | 14.56% |
| Dec 31, 2021 | -232.80% |
| Sep 30, 2021 | 174.60% |
| Jun 30, 2021 | -126.41% |
| Mar 31, 2021 | 355.13% |
| Dec 31, 2020 | -46.19% |
| Mar 31, 2020 | -67.51% |
| Dec 31, 2019 | 293.06% |
| Mar 31, 2019 | -112.11% |
| Dec 31, 2018 | 215.44% |
| Sep 30, 2018 | 180.99% |
| Jun 30, 2018 | -279.46% |
| Mar 31, 2018 | 178.10% |
| Dec 31, 2017 | -188.39% |
| Sep 30, 2017 | 174.88% |